{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:51:57Z","timestamp":1788814317910,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"University of Waterloo, School of Pharmacy","award":["Intradisciplinary Seed Fund"],"award-info":[{"award-number":["Intradisciplinary Seed Fund"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40273-025-01484-1","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T22:17:05Z","timestamp":1743718625000},"page":"765-778","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9719-6508","authenticated-orcid":false,"given":"Sam","family":"Hirniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea N.","family":"Edginton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Iorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W. L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,1]]},"reference":[{"key":"1484_CR1","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2209226","volume":"388","author":"A von Drygalski","year":"2023","unstructured":"von Drygalski A, Chowdary P, Kulkarni R, et al. Efanesoctocog alfa prophylaxis for patients with severe hemophilia A. N Engl J Med. 2023;388:310\u20138.","journal-title":"N Engl J Med"},{"key":"1484_CR2","unstructured":"FDA approves once-weekly ALTUVIIIO\u2122 A new class of factor VIII therapy for hemophilia A that offers significant bleed protection. Paris and Stockholm: Sanofi; 2023."},{"key":"1484_CR3","unstructured":"Pharmacoeconmic Report: Emicizumab (HEMLIBRA). 2021. February 2021."},{"key":"1484_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101164","volume":"64","author":"HAH Abdelgawad","year":"2024","unstructured":"Abdelgawad HAH, Foster R, Otto M. Nothing short of a revolution: novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A. Blood Rev. 2024;64: 101164.","journal-title":"Blood Rev"},{"key":"1484_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/hae.14723","volume":"29","author":"JK Yu","year":"2023","unstructured":"Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. Haemophilia. 2023;29:488\u201397.","journal-title":"Haemophilia"},{"key":"1484_CR6","doi-asserted-by":"publisher","first-page":"13041","DOI":"10.1182\/blood-2022-162276","volume":"140","author":"M Decker-Palmer","year":"2022","unstructured":"Decker-Palmer M, Lin C-W, Wilson M, et al. Cost-effectiveness of emicizumab for prophylaxis in people with severe hemophilia A without inhibitors. Blood. 2022;140:13041\u20132.","journal-title":"Blood"},{"key":"1484_CR7","first-page":"1697","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA. Emicizumab: a review in haemophilia A. Drugs (New York, NY). 2019;79:1697\u2013707.","journal-title":"Drugs (New York, NY)"},{"key":"1484_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.vhri.2022.10.007","volume":"34","author":"RM Camelo","year":"2023","unstructured":"Camelo RM, Barbosa MM, Ara\u00fajo MS, et al. Economic evaluation of immune tolerance induction in children with severe hemophilia A and high-responding inhibitors: a cost-effectiveness analysis of prophylaxis with emicizumab. Value Health Reg Issues. 2023;34:31\u20139.","journal-title":"Value Health Reg Issues"},{"key":"1484_CR9","first-page":"477","volume":"5","author":"N Al-Rahal","year":"2022","unstructured":"Al-Rahal N, Ahmed OAN, Alwataify S, Almusawi IM. Emicizumab prophylaxis every four weeks among hemophilia A with inhibitors in Iraq, multicenter study. J Reattach Ther Dev Diversities. 2022;5:477\u201382.","journal-title":"J Reattach Ther Dev Diversities"},{"key":"1484_CR10","doi-asserted-by":"publisher","first-page":"S845","DOI":"10.1016\/j.jval.2019.09.2358","volume":"22","author":"PA Cortesi","year":"2019","unstructured":"Cortesi PA, Castaman G, Trifir\u00f2 G, et al. PRO28 Emicizumab prophylaxis in haemophilia A patients with inhibitors: a cost-effectiveness and budget impact analysis. Value Health. 2019;22:S845.","journal-title":"Value Health"},{"key":"1484_CR11","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task Force\u20131. Med Decis Mak. 2012;32:667\u201377.","journal-title":"Med Decis Mak"},{"key":"1484_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/0272989X12454579","volume":"32","author":"DM Eddy","year":"2012","unstructured":"Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force-7. Med Decis Mak. 2012;32:733\u201343.","journal-title":"Med Decis Mak"},{"key":"1484_CR13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.jval.2012.06.016","volume":"15","author":"M Roberts","year":"2012","unstructured":"Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Value Health. 2012;15:804\u201311.","journal-title":"Value Health"},{"key":"1484_CR14","unstructured":"Rind DM, Agboola F, Herron-Smith S, Quach D, Chapman R, Pearson SD. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value (2020)"},{"key":"1484_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/hae.13631","volume":"25","author":"SC Gouw","year":"2019","unstructured":"Gouw SC, Timmer MA, Srivastava A, et al. Measurement of joint health in persons with haemophilia: a systematic review of the measurement properties of haemophilia-specific instruments. Haemophilia. 2019;25:e1\u201310.","journal-title":"Haemophilia"},{"key":"1484_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/13696998.2020.1721508","volume":"23","author":"K Cook","year":"2020","unstructured":"Cook K, Forbes SP, Adamski K, Ma JJ, Chawla A, Garrison LP. Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A. J Med Econ. 2020;23:501\u201312.","journal-title":"J Med Econ"},{"key":"1484_CR17","first-page":"e375","volume":"22","author":"K Fischer","year":"2016","unstructured":"Fischer K, Lewandowski D, Janssen MP. Modelling lifelong effects of different prophylactic treatment strategies for severe haemophilia A. Haemophilia Off J World Fed Hemoph. 2016;22:e375\u201382.","journal-title":"Haemophilia Off J World Fed Hemoph"},{"key":"1484_CR18","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/hae.13023","volume":"22","author":"PM Poonnoose","year":"2016","unstructured":"Poonnoose PM, Hilliard P, Doria AS, et al. Correlating clinical and radiological assessment of joints in haemophilia: results of a cross sectional study. Haemophilia Off J World Fed Hemoph. 2016;22:925\u201333.","journal-title":"Haemophilia Off J World Fed Hemoph"},{"key":"1484_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1182\/blood.2021010864","volume":"138","author":"NS Bolous","year":"2021","unstructured":"Bolous NS, Chen Y, Wang H, et al. The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood. 2021;138:1677\u201390.","journal-title":"Blood"},{"key":"1484_CR20","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/ejh.13901","volume":"110","author":"N Kragh","year":"2023","unstructured":"Kragh N, Tytula A, Pochopien M, et al. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK. Eur J Haematol. 2023;110:262\u201370.","journal-title":"Eur J Haematol"},{"key":"1484_CR21","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1182\/blood-2023-181062","volume":"142","author":"R Curtis","year":"2023","unstructured":"Curtis R, Decker-Palmer M, Wilson MR, et al. Cost-effectiveness of emicizumab vs efanesoctocog alfa, standard half life (SHL) and other extended half life (EHL) FVIII products for prophylaxis in people with severe hemophilia a without inhibitors. Blood. 2023;142:5053.","journal-title":"Blood"},{"key":"1484_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood-2023-190420","volume":"142","author":"S Ito","year":"2023","unstructured":"Ito S, Potnis KC, Allen C, et al. Equitable care for severe hemophilia_A: distributional cost-effectiveness of prophylactic weekly efanesoctocog alfa versus standard-care factor VIII in patients with severe hemophilia_A in the United States. Blood. 2023;142:492.","journal-title":"Blood"},{"key":"1484_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/hae.14979","volume":"30","author":"SE Hirniak","year":"2024","unstructured":"Hirniak SE, Iorio A, Alsabbagh M, Hajducek D, Wong W. Health utilities in adults with hemophilia A: a retrospective cohort study. Haemophilia. 2024;30:733\u201342.","journal-title":"Haemophilia"},{"key":"1484_CR24","doi-asserted-by":"publisher","DOI":"10.2196\/resprot.6558","volume":"5","author":"A Iorio","year":"2016","unstructured":"Iorio A, Keepanasseril A, Foster G, et al. Development of a web-accessible population pharmacokinetic service\u2014Hemophilia (WAPPS-Hemo): study protocol. JMIR Res Protoc. 2016;5: e239.","journal-title":"JMIR Res Protoc"},{"key":"1484_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/hae.14979","volume":"30","author":"S Hirniak","year":"2024","unstructured":"Hirniak S, Edginton AN, Iorio A, Alsabbagh MW, Hajducek DM, Wong WW. Health utilities in adults with hemophilia A: a retrospective cohort study. Haemophilia. 2024;30:733\u201342.","journal-title":"Haemophilia"},{"key":"1484_CR26","unstructured":"Factor VIII concentrates. In: RED BOOK. Merative. https:\/\/www.micromedexsolutions.com\/. Accessed 24 May 2024."},{"key":"1484_CR27","unstructured":"Statistics C. Purchasing power parities, 2019. Vol 2021. 2020."},{"key":"1484_CR28","unstructured":"Getting Health Care: Wait Times. Ontario Health; 2023. https:\/\/www.ontariohealth.ca\/public-reporting\/wait-times. Accessed 12 Sept 2024."},{"key":"1484_CR29","doi-asserted-by":"publisher","first-page":"e12690","DOI":"10.1002\/rth2.12690","volume":"6","author":"J St-Louis","year":"2022","unstructured":"St-Louis J, Abad A, Funk S, et al. The Hemophilia Joint Health Score version 2.1 validation in adult patients study: a multicenter international study. Res Pract Thromb Haemost. 2022;6:e12690.","journal-title":"Res Pract Thromb Haemost"},{"key":"1484_CR30","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1111\/hae.13231","volume":"23","author":"M Osooli","year":"2017","unstructured":"Osooli M, Steen Carlsson K, Baghaei F, et al. The association between health utility and joint status among people with severe haemophilia A: findings from the KAPPA register. Haemophilia. 2017;23:e180\u20137.","journal-title":"Haemophilia"},{"key":"1484_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.arth.2015.07.031","volume":"31","author":"A Hart","year":"2016","unstructured":"Hart A, Antoniou J, Brin YS, Huk OL, Zukor DJ, Bergeron SG. Simultaneous bilateral versus unilateral total knee arthroplasty: a comparison of 30-day readmission rates and major complications. J Arthroplasty. 2016;31:31\u20135.","journal-title":"J Arthroplasty"},{"issue":"Suppl 1","key":"1484_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/17453674.2016.1181817","volume":"87","author":"ER Bohm","year":"2016","unstructured":"Bohm ER, Molodianovitsh K, Dragan A, et al. Outcomes of unilateral and bilateral total knee arthroplasty in 238,373 patients. Acta Orthop. 2016;87(Suppl 1):24\u201330.","journal-title":"Acta Orthop"},{"key":"1484_CR33","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/hae.13327","volume":"23","author":"IAR Kuijlaars","year":"2017","unstructured":"Kuijlaars IAR, Timmer MA, de Kleijn P, Pisters MF, Fischer K. Monitoring joint health in haemophilia: factors associated with deterioration. Haemophilia. 2017;23:934\u201340.","journal-title":"Haemophilia"},{"key":"1484_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/PPA.S202773","volume":"13","author":"L Carroll","year":"2019","unstructured":"Carroll L, Benson G, Lambert J, Benmedjahed K, Zak M, Lee XY. Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom. Patient Prefer Adherence. 2019;13:941\u201357.","journal-title":"Patient Prefer Adherence"},{"key":"1484_CR35","unstructured":"Statistics C. Life Tables, Canada, Provinces and Territories, 1980\/1982 to 2017\/2019. Ottawa: Government of Canada; 2020."},{"key":"1484_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jth.15182","volume":"19","author":"S Hassan","year":"2021","unstructured":"Hassan S, Monahan RC, Mauser-Bunschoten EP, et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001\u20132018. J Thromb Haemost. 2021;19:645\u201353.","journal-title":"J Thromb Haemost"},{"key":"1484_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijscr.2016.10.046","volume":"29","author":"A Hegde","year":"2016","unstructured":"Hegde A, Nair R, Upadhyaya S. Spontaneous intracerebral hemorrhage in hemophiliacs-A treatment dilemma. Int J Surg Case Rep. 2016;29:17\u20139.","journal-title":"Int J Surg Case Rep"},{"key":"1484_CR38","unstructured":"Rind DM, Agboola F, Herron-Smith S, Quach D, Chapman R, Pearson SD, Bradt P. Valoctocogene roxaparvovec and emicizumab for hemophilia A without inhibitors: effectiveness and value. Institute for Clinical and Economic Review; 2020. 20 Nov 2020."},{"key":"1484_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2516.2005.01082.x","volume":"11","author":"HE Heemstra","year":"2005","unstructured":"Heemstra HE, Zwaan T, Hemels M, et al. Cost of severe haemophilia in Toronto. Haemophilia Off J World Fed Hemoph. 2005;11:254\u201360.","journal-title":"Haemophilia Off J World Fed Hemoph"},{"key":"1484_CR40","unstructured":"CJRR annual report: Hip and knee replacements in Canada\u00a0CIHI; 2021."},{"key":"1484_CR41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MLR.0000000000000447","volume":"54","author":"F Xie","year":"2016","unstructured":"Xie F, Pullenayegum E, Gaebel K, et al. A time trade-off-derived value set of the EQ-5D-5L for Canada. Med Care. 2016;54:98\u2013105.","journal-title":"Med Care"},{"key":"1484_CR42","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00330-015-4013-8","volume":"26","author":"W Foppen","year":"2016","unstructured":"Foppen W, van der Schaaf IC, Beek FJA, Verkooijen HM, Fischer K. Scoring haemophilic arthropathy on X-rays\u202f: improving inter- and intra-observer reliability and agreement using a consensus atlas. Eur Radiol. 2016;26:1963\u201370.","journal-title":"Eur Radiol"},{"key":"1484_CR43","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2018021345","volume":"2","author":"N Machin","year":"2018","unstructured":"Machin N, Ragni MV, Smith KJ. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Adv. 2018;2:1792\u20138.","journal-title":"Blood Adv"},{"key":"1484_CR44","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1186\/s13018-023-04409-w","volume":"18","author":"M Bordbar","year":"2023","unstructured":"Bordbar M, Beigipour R, Tahami M, Zekavat OR, Haghpanah S, Moshfeghinia R. Skeletal complications in patients with hemophilia: a single-center experience. J Orthop Surg Res. 2023;18:907.","journal-title":"J Orthop Surg Res"},{"key":"1484_CR45","unstructured":"Hirniak SE, A; Iorio, A; Alsabbagh, M; Hajducek, D; Wong, W. Health system cost associated with hemophilia A: a population-based analysis. Paper presented at: Society of Medical Decision Making Annual Meeting; 2025. Ann Arbour."},{"key":"1484_CR46","first-page":"1","volume":"2","author":"A Iorio","year":"2022","unstructured":"Iorio A, Grenier S, Page D, et al. Reflections on the Canadian Bleeding Disorders Registry: lessons learned and future perspectives. Can J Health Technol. 2022;2:1\u201315.","journal-title":"Can J Health Technol"},{"key":"1484_CR47","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0178","volume":"13","author":"C Balijepalli","year":"2024","unstructured":"Balijepalli C, Gullapalli L, Joshy J, Rawson NS. The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health. J Comp Eff Res. 2024;13: e230178.","journal-title":"J Comp Eff Res"},{"key":"1484_CR48","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1001\/jama.2016.11237","volume":"316","author":"AS Kesselheim","year":"2016","unstructured":"Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA J Am Med Assoc. 2016;316:858\u201371.","journal-title":"JAMA J Am Med Assoc"},{"key":"1484_CR49","unstructured":"Cadth. Emicizumab (HEMLIBRA). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2021."},{"key":"1484_CR50","first-page":"A219","volume":"20","author":"H Fang","year":"2017","unstructured":"Fang H, Chen C, Han L, Wu J. Cost-effectiveness analysis of standard prophylaxis versus on-demand treatment in severe hemophilia a in China. Value Health. 2017;20:A219.","journal-title":"Value Health"},{"key":"1484_CR51","unstructured":"Valentino L, Meyers S, Phelan K. ICER Hemophilia Comment-Folio\u2014Draft Scoping Document Review. Boston; 2022. 25 May 25 2022."},{"key":"1484_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102180","volume":"7","author":"BA Konkle","year":"2023","unstructured":"Konkle BA, Oldenburg J, Pasi J, et al. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults. Res Pract Thromb Haemost. 2023;7: 102180.","journal-title":"Res Pract Thromb Haemost"},{"key":"1484_CR53","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1182\/blood-2016-02-683169","volume":"129","author":"MJ Manco-Johnson","year":"2017","unstructured":"Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129:2368\u201374.","journal-title":"Blood"},{"key":"1484_CR54","first-page":"35","volume":"22","author":"M Shields","year":"2011","unstructured":"Shields M, Connor Gorber S, Janssen I, Tremblay MS. Bias in self-reported estimates of obesity in Canadian health surveys: an update on correction equations for adults. Health Rep. 2011;22:35\u201345.","journal-title":"Health Rep"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01484-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01484-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T11:01:52Z","timestamp":1749898912000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01484-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1484"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01484-1","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"assertion":[{"value":"10 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was granted by UW REB # 44471 and #44100.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"S Hirniak: No conflicts to declare. A Edginton: No conflicts to declare. A Iorio: McMaster University (the institution where A Iorio is based) has received project-based funding via research or service agreements within the past 36 months from: Bayer, Biomarin, CSL, Freeline, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Sobi, Spark, Takeda, Uniqure. None were received for this project. W Wong:  Has received consulting fees from Hemolytic Inc from Jan 3rd, 2024-Jan 31st 2024.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}